With its significant cash infusions from offloading its COVID assets, Novavax had just over $1 billion as it exited Q3, 2024.
Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational ...
Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback